Most Read Articles
Elvira Manzano, 13 Sep 2017
Tisagenlecleucel, now US FDA approved, has made history as the first ever chimeric antigen receptor (CAR) T-cell therapy for B-cell precursor acute lymphoblastic leukaemia (ALL) – a breakthrough that has the potential to transform treatment for blood cancers that have not responded to standard therapies.
16 Jun 2015
Anastrozole is more effective than tamoxifen in preventing breast cancer recurrence in postmenopausal women with ductal carcinoma in situ who have undergone lumpectomy and radiation therapy, a recent phase III randomized trial has shown.
Christina Lau, 09 May 2017

Treatment with osimertinib significantly improves symptoms in patients with advanced non-small-cell lung cancer (NSCLC), according to new data from the phase III AURA3 trial presented at the European Lung Cancer Conference (ELCC) 2017.

Accelerated elozutumab infusion safe for multiple myeloma

08 Sep 2017

Accelerated administration of elotuzumab for multiple myeloma (MM) or relapsed/refractory MM (RRMM) is safe and produces no grade 3 or 4 infusion reactions (IRs), a phase 2 study shows.

Investigators involved 70 adults with active and newly diagnosed MM or RRMM (median age 67.5 years). Of these, 47 percent (n=33) had received prior treatments for MM, the most common of which was bortezomib (41 percent).

Infusion rate of the first dose of elotuzumab during cycle 1 was increased from 0.5 to 2 mL/min in the absence of IRs. Rates were increased from 3 to 4 mL/min during dose 2 and to mL/min for all succeeding doses. Of all infusions, 87 percent (n=968) were delivered at the maximum rate of 5 mL/min.

There were no reported cases of the primary outcome of grade 3 or 4 IRs by the end of cycle 2. Only two IRs were reported, both of which manifested during the 2 mL/min infusion rate. One patient experienced a nonspecific grade 2 infusion-related reaction, while the other had a grade 1 pyrexia.

Infusion was interrupted only in the case of the grade 2 IR but was resumed after resolution. No treatments were discontinued due to IRs.

The most common adverse event (AE) was infection which was observed in 60 percent (n=42) of the participants. This was followed by fatigue (50 percent; n=35) and diarrhoea (31 percent; n=22). Eight cases of grade 4 AEs were reported and 13 patients discontinued treatment because of AEs.

A total of 27 patients experienced severe AEs, the most common of which were pneumonia and atrial fibrillation which were observed in three patients each. There was a total of five deaths caused by disease progression, fatal bleeding, respiratory failure and ischaemic bowel syndrome.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Elvira Manzano, 13 Sep 2017
Tisagenlecleucel, now US FDA approved, has made history as the first ever chimeric antigen receptor (CAR) T-cell therapy for B-cell precursor acute lymphoblastic leukaemia (ALL) – a breakthrough that has the potential to transform treatment for blood cancers that have not responded to standard therapies.
16 Jun 2015
Anastrozole is more effective than tamoxifen in preventing breast cancer recurrence in postmenopausal women with ductal carcinoma in situ who have undergone lumpectomy and radiation therapy, a recent phase III randomized trial has shown.
Christina Lau, 09 May 2017

Treatment with osimertinib significantly improves symptoms in patients with advanced non-small-cell lung cancer (NSCLC), according to new data from the phase III AURA3 trial presented at the European Lung Cancer Conference (ELCC) 2017.